From apremilast to JAK inhibitors—salvage treatment strategies for refractory palmoplantar pustulosis: case series
For refractory PPP patients who fail APR therapy, switching to JAK inhibitors serves as an effective rescue treatment strategy, with most patients achieving remission within a short period and demonstrating good tolerability. This approach offers a viable treatment option for PPP that has proven resistant to conventional therapies and phosphodiesterase-4 (PDE4) inhibitors. Still, its long-term efficacy and safety require validation through large-scale prospective studies.
Authors
- H M Zhang
- Fanzhang Meng (ORCID: https://orcid.org/0009-0008-3427-5666)
- Cui Guo (ORCID: https://orcid.org/0000-0002-2499-9248)
- Jingjing Ma (ORCID: https://orcid.org/0000-0001-9011-3372)
- Di Jin (ORCID: https://orcid.org/0000-0002-5202-0025)
- Yufeng Pan (ORCID: https://orcid.org/0009-0006-2392-4830)
- Chen Li
- Jianong Tang
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Beijing University of Chinese Medicine (CN)
- Weifang People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fmed.2026.1743408
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China